Update on Availability of Cimerli, a Biosimilar to Lucentis
Cimerli is supplied as a single-dose glass vial designed to deliver 0.05mL of 10mg/mL or 6mg/mL ranibizumab-eqrn solution for intravitreal injection.
Age-Related Macular Degeneration
Cimerli Approved as Interchangeable Biosimilar to Lucentis
The approval of Cimerli was based on a comprehensive analytical, preclinical and clinical program including the phase 3 COLUMBUS-AMD study.
Intravitreal Pegcetacoplan Gets Priority Review for Geographic Atrophy
Pegcetacoplan is a targeted C3 therapy that works by regulating excessive activation of the complement cascade.
Pegcetacoplan Continues to Reduce Geographic Atrophy Lesion Growth: 18-Month Data
DERBY and OAKS are phase 3, multicenter, randomized, double-masked, sham-controlled studies.
Trials Show Promise for Intravitreal Faricimab in Retinal Disease
Faricimab noninferior to aflibercept for visual acuity gains in neovascular age-related macular degeneration, diabetic macular edema
January 2022: 5 Notable Drug Approvals
Review the January 2022 notable drug approvals.
Vabysmo Approved for Wet AMD, Diabetic Macular Edema
Vabysmo is a humanized bispecific antibody that works by inhibiting the angiopoietin-2 (Ang-2) and vascular endothelial growth factor-A (VEGF-A) pathways.
New Drug Product: Susvimo
This slideshow shows drug information for Susvimo. Click here for the complete Susvimo monograph.
Susvimo Approved for Wet Age-Related Macular Degeneration
Susvimo delivers ranibizumab via ocular implant, which is surgically inserted into the eye during a one-time, outpatient procedure and refilled every 6 months.
Faricimab Gets Priority Review for Wet AMD, Diabetic Macular Edema
The BLA submission is based on positive results across four phase 3 studies in wet AMD and DME.
